Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned an average recommendation of "Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $23.00.

Several equities research analysts have recently commented on the company. HC Wainwright boosted their price objective on Stoke Therapeutics from $35.00 to $47.00 and gave the company a "buy" rating in a report on Tuesday, February 18th. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, February 18th. Chardan Capital reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th.

Insiders Place Their Bets

In related news, General Counsel Jonathan Allan sold 13,666 shares of the stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $13.61, for a total transaction of $185,994.26. Following the completion of the transaction, the general counsel now owns 21,476 shares in the company, valued at approximately $292,288.36. This represents a 38.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Barry Ticho sold 2,586 shares of the firm's stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $33,592.14. Following the sale, the insider now owns 44,746 shares of the company's stock, valued at $581,250.54. This trade represents a 5.46 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 62,849 shares of company stock valued at $809,421. Corporate insiders own 11.30% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of STOK. RTW Investments LP lifted its stake in Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after purchasing an additional 471,240 shares during the last quarter. Baker BROS. Advisors LP raised its stake in shares of Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company's stock valued at $51,111,000 after buying an additional 265,395 shares during the period. Toronto Dominion Bank purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at $35,001,000. State Street Corp grew its stake in shares of Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after acquiring an additional 137,145 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in shares of Stoke Therapeutics by 2.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company's stock worth $14,901,000 after acquiring an additional 38,446 shares during the period.

Stoke Therapeutics Price Performance

Shares of STOK stock traded down $0.14 on Tuesday, reaching $7.85. 661,998 shares of the company were exchanged, compared to its average volume of 855,024. The company has a 50-day moving average of $10.27 and a 200-day moving average of $12.12. The company has a market cap of $415.79 million, a price-to-earnings ratio of -3.74 and a beta of 0.95. Stoke Therapeutics has a one year low of $5.60 and a one year high of $17.58.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.